Lt. Gov. Coleman and several of Kentucky’s female legislators joined UK HealthCare to highlight the work of the Markey Cancer Center's Ovarian Cancer Screening Program.
The initiative aims to create a connected, integrated statewide cancer provider network. 40% of all new cancer cases in Kentucky are directly or indirectly cared for by Markey.
The UK Markey Cancer Center has officially launched a unique new clinical trial to test whether Artemisia annua extract can prevent ovarian cancer recurrence.
The curriculum includes information on cancer data and risk factors in the region, follows national and state science and health education standards, and is tailored to cultural aspects of Appalachian Kentucky.
The University of Kentucky Markey Cancer Center is teaming up with the National Comprehensive Cancer Network® (NCCN®), the American Cancer Society (ACS) and other leading cancer organizations across the country to endorse the resumption of cancer screening and treatment during the ongoing COVID-19 pandemic.
A new study by UK Markey Cancer Center researchers shows that DACH1 mutations are prevalent in Kentucky patients with endometrial cancer, suggesting that DACH1 may be a candidate biomarker for future trials with immunotherapy.
A major initiative of Williams and the Markey Community Impact Office will be the organization and expansion of Markey’s research and outreach portfolio that is focused on reducing cancer and other health disparities based on race/ethnicity, socioeconomic status, etc.
Building on these findings, Plattner and Markey oncologists are now collaborating with the pharmaceutical company Novartis to develop a Phase I clinical trial to test the safety and effectiveness of using nilotinib in relapsed melanoma patients.
Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
Recently published in PLOS One, the study used Kentucky Cancer Registry patient data from 2007-2011 to identify trends in epidermal growth factor receptor (EGFR) mutation testing and the usage of the EGFR inhibitor, erlotinib.
